A Phase 2 interventional study of GT005 in Dry Age-related Macular Degeneration, sponsored by Gyroscope Therapeutics Limited. Terminated at 55 sites in 8 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-01-27.
Sponsored by Gyroscope Therapeutics Limited · Phase 2, Interventional, and Treatment
The purpose of this clinical study was to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to age-related macular degeneration (AMD).
This was a Phase II, outcomes assessor-masked, multicentre, randomized study to assess the safety and efficacy of two doses of GT005 administered as a single-time subretinal injection in subjects with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD). Approximately 202 subjects were planned to be randomized to GT005 or the untreated control group.
Subjects entered the study had genotyping and serum complement factor I(CFI) levels assessed. Assessments were either performed at a sponsor-approved laboratory during the EXPLORE screening period or provided through participation in a previous Gyroscope sponsored study. If subjects failed to meet the eligibility criteria for EXPLORE, they were classified as screen failures for this study and could be considered for entry into another Novartis/Gyroscope sponsored study.
After providing the informed consent, subjects underwent ophthalmic and clinical assessments to determine eligibility for inclusion in the study.
Upon confirmation of eligibility, subjects in part 1 were randomized to one of two groups: low dose [2E10 vg], or high dose [2E11 vg]. Within each group, subjects were allocated to GT005 or untreated control based on a 2:1 ratio. Once part 1 enrolment was completed, and the last active subject completed screening and either was screen-failed or randomized, then Part 2 could commence. In part 2, subjects were randomized to the low dose [2E10] group or untreated control based on a 2:1 ratio. The study eye was identified for all subjects.
Subjects were stratified by GA lesion size on fundus autofluorescence (FAF) (≤10 mm2 or >10 mm2) and presence of choroidal neovascularisation (CNV) in the fellow eye (Yes or No). Randomization of study eyes in the GA lesion size upper stratum of >10 mm2 to 17.5 mm2 was capped at 20% of total subjects randomized. Once enrolment capping at 20% based on the upper GA lesion size was reached, eyes that fulfilled the cap criteria were no longer eligible, unless the subject had a CFI rare variant genotype (minor allele frequency ≤1%) previously associated with normal or low serum CFI or had an unreported CFI rare variant genotype. Of all subjects enrolled and randomized in the study, the presence of CNV in the fellow eye was capped at 25% per stratum. A permuted-block randomization method was used to obtain an approximately 2:1 ratio between GT005 and the untreated control groups for each dose group within each stratum.
Following randomization, the investigator was informed of the subject's allocated treatment (GT005 or the untreated control group) and the study eye selected. To minimize bias, all imaging endpoint assessments and grading were performed at a Central Reading Centre (CRC), in a masked fashion. For part 1, the Sponsor, subject, investigators, and study personnel performing clinical assessments remained masked to dose received for those allocated to GT005. For part 2, the Sponsor, investigators, subjects, and study personnel performing clinical assessments were unmasked to dose received, since only the low dose was administered.
Subjects randomized to GT005 underwent a single time subretinal administration of the study drug. Vitreous samples were collected during surgery. Following surgery, a prophylactic steroid regimen was prescribed.
The study consisted of a screening period lasting up to 8 weeks (or up to 12 weeks if agreed by the Sponsor Medical Monitor), followed by a 96-week study period. All subjects were assessed for the occurrence of adverse events (AEs) at each visit and underwent functional visual and retinal imaging,anatomical assessments, and biological sampling as per the schedule of assessments.
This study was conducted in compliance with Independent ethics committees (IECs) / Institutional review board (IRBs), informed consent regulations, the Declaration of Helsinki, International Council on Harmonisation (ICH) Good Clinical Practices (GCP) Guidelines, and the Food and Drug Administration (FDA) guidance.
On 24-Aug-2023, the decision was taken to terminate the study and the GT005 program. The decision was aligned with the recommendation of an independent DMC, which concluded that futility criteria had been met for the HORIZON study (GT005-03) and the overall benefit-risk ratio did not support continuation of the current development program as planned. All GT005- treated subjects, who were willing to be transferred into the long-term safety follow-up study were enrolled in the ORACLE (CPPY988A12203B / NCT05481827) study.
In both Part 1 and Part 2, patients with geographic atrophy secondary to age-related macular degeneration were enrolled. In Part 1, patients with CFI rare variant genotype and low serum CFI level and in Part 2, patients were enrolled regardless of genotypes. Efficacy results were analyzed by arm and also by part. AE and disposition data were reported per arm, but the parts were combined, according to the analysis plan.
Part 1 enrolled subjects with CFI rare variant; Part 2 enrolled subjects regardless of genotype.
There were no subjects in the high dose arm in Part 2.
Up to 25% of the enrolled study population are permitted to have CNV in the fellow eye, defined as either:
Exclusion Criteria:
GT005 Low dose \[2E10 vg\] (Parts 1 and 2)
Drug: GT005
GT005 High dose \[2E11 vg\] (Part 1)
Drug: GT005
Untreated control (Parts 1 and 2)
GT005 is a recombinant, non-replicating AAV2 expressing human complement factor I (CFI). GT005 was administered as a single time subretinal injection into the study eye of subjects allocated to one of the two GT005 doses.
The Change From Baseline to Week 48 in Geographic Atrophy (GA) - Part 1
The change from baseline to Week 48 in GA area as measured by fundus autofluorescence (FAF)
Time frame: Baseline, Weeks 12, 24, 36, and 48
The Change From Baseline in Geographic Atrophy (GA) at Week 72 and Week 96 - Part 1
The change from baseline to Week 48 in GA area as measured by fundus autofluorescence (FAF)
Time frame: Baseline, Weeks 72 and 96
Summary of Adverse Events - Parts 1 and 2 Combined
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs.
Time frame: Adverse events are reported from randomization up to end of study, for a maximum timeframe of approximately 96 weeks.
Ocular Adverse Events by Primary System Organ Class and Preferred Term for the Study Eye - Parts 1 and 2 Combined
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs. System organ classes are sorted alphabetically, and preferred terms are sorted by decreasing overall frequency within system organ class.
Time frame: Adverse events are reported from randomization up to end of study, for a maximum timeframe of approximately 96 weeks.
Non-ocular Adverse Events - Summary - Parts 1 and 2 Combined
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs.
Time frame: Adverse events are reported from randomization up to end of study, for a maximum timeframe of approximately 96 weeks.
Change in GA Morphology From Baseline to Week 96 on Colour Fundus Photography (CFP) - Number of Participants With Increase in Fundus Autofluorescence (FAF) - Part 1
Change in GA morphology on multimodal imaging through Week 96. FAF images at Week 5 were introduced via a protocol amendment after most participants had already completed Week 5; therefore, only a minimal number of patients had FAF images taken at Week 5 for Part 1.
Time frame: Baseline, Weeks 5,12,24,36,48,72,96
Change From Baseline to Week 48 in GA Morphology on Colour Fundus Photography (CFP) - Number of Participants With Increase in Fundus Autofluorescence - Part 2
Change in GA morphology on multimodal imaging through Week 48. For the untreated control group, there were no protocol-specified visits for Weeks 5 and 8. The untreated control participants were immediately discontinued from the study when the study was early terminated; therefore Week 36 and 48 data in part 2 were not applicable for these the untreated control group.
Time frame: Baseline, Weeks 5,12,24,36,48
Change in Best Corrected Visual Acuity (BCVA) Score From Baseline Through Week 96 Via the Early Treatment for Diabetic Retinopathy (ETDRS) Chart - Part 1
BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. Min and max possible scores are 0-100 respectively. A higher score represents better visual functioning. For the untreated control group, there were no protocol-specified visits for Weeks 1, 5 and 8.
Time frame: Baseline, Weeks 1, 5, 8, 12, 24, 36, 48, 72 and 96
Change in Low Luminance Difference (LLD) Letter Count From Baseline at Weeks 12, 24, 36, 48, 72 and 96, Via Early Treatment for Diabetic Retinopathy (ETDRS) Chart - Part 1
LLD was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. The test was to be performed after BCVA testing, prior to pupil dilation, and distance refraction was to be carried out before Low Luminance Visual Acuity (LLVA) was measured. LLVA was to be measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. The LLD was calculated as the difference between BCVA and LLVA. Initially, letters were to be read at a distance of 4 metres from the chart. If \<20 letters were read at 4 metres, testing at 1 metre should have been performed. LLD was to be reported as number of letters read correctly by the subject. Min and max possible scores are 0-100 respectively. A higher score represents better visual functioning.
Time frame: Baseline, Weeks 12, 24, 36, 48, 72 and 96
Change in Low Luminance Difference (LLD) Letter Count From Baseline at Weeks 12, 24, 36, and 48, Via Early Treatment for Diabetic Retinopathy (ETDRS) Chart - Part 2
LLD was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. The test was to be performed after BCVA testing, prior to pupil dilation, and distance refraction was to be carried out before Low Luminance Visual Acuity (LLVA) was measured. LLVA was to be measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. The LLD was calculated as the difference between BCVA and LLVA. Initially, letters were to be read at a distance of 4 metres from the chart. If \<20 letters were read at 4 metres, testing at 1 metre should have been performed. LLD was to be reported as number of letters read correctly by the subject. Min and max possible scores are 0-100 respectively. A higher score represents better visual functioning.
Time frame: Baseline, Weeks 12, 24, 36, and 48
Change From Baseline at Weeks 24, 36, 48, 72 and 96 in Reading Performance, Measured as the Maximum Reading Speed (Words Per Minute), as Assessed by Minnesota Low-vision Reading Test (MNRead) Chart - Part 1
The maximum reading speed (MRS) represents the highest reading speed an individual can achieve when print size is not a limiting factor. Essentially, it measures how quickly a person can read text when the print is large enough to be easily readable. A higher count represents better visual functioning.
Time frame: Baseline, Weeks 24, 36, 48, 72 and 96
Change From Baseline at Weeks 24, 36 and 48 in Reading Performance, Measured as the Maximum Reading Speed (Words Per Minute), as Assessed by Minnesota Low-vision Reading Test (MNRead) Chart - Part 2
A higher count represents better visual functioning. The untreated control participants were immediately discontinued from the study when the study was early terminated; therefore Week 36 and 48 data in part 2 were not applicable for these the untreated control group.
Time frame: Baseline, Weeks 24, 36 and 48
Change From Baseline at Weeks 24, 36, 48, 72 and 96 in Functional Reading Independence (FRI) Index - Part 1
The FRI index is a patient-reported outcome measure developed specifically for use in GA patients. The FRI index evaluates the level of independence subjects have in performing everyday activities that require reading, such as writing a cheque or reading a prescription. Scores derived from the index range from 1 (unable to do) to 4 (total independence). A higher score represents better visual functioning.
Time frame: Baseline, Weeks 24, 36, 48, 72 and 96
Change From Baseline at Weeks 24, 36 and 48 in Functional Reading Independence (FRI) Index - Part 2
The FRI index is a patient-reported outcome measure developed specifically for use in GA patients. The FRI index evaluates the level of independence subjects have in performing everyday activities that require reading, such as writing a cheque or reading a prescription. Scores derived from the index range from 1 (unable to do) to 4 (total independence). A higher score represents better visual functioning. The untreated control participants were immediately discontinued from the study when the study was early terminated; therefore Week 36 and 48 data in part 2 were not applicable for these the untreated control group.
Time frame: Baseline, Weeks 24, 36 and 48
Change From Baseline at Weeks 24, 36, 48, 72 and 96 in Patient Reported Outcomes (Visual Function Questionnaire-25) - Composite Score - Part 1
The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains. The NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.
Time frame: Baseline, Weeks 24, 36, 48, 72 and 96
Change From Baseline at Weeks 24, 36 and 48 in Patient Reported Outcomes (Visual Function Questionnaire-25) - Composite Score - Part 2
The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains. The NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales. The untreated control participants were immediately discontinued from the study when the study was early terminated; therefore Week 36 and 48 data in part 2 were not applicable for these the untreated control group.
Time frame: Baseline, Weeks 24, 36, and 48
This was a randomized, controlled study designed to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with GA secondary to AMD. This was a study conducted in 3 treatment arms (GT005 low dose, GT005 high dose, and an untreated control group) and in 2 parts (Part 1 enrolled subjects with Complement factor I (CFI) rare variant; Part 2 enrolled subjects regardless of genotype (i.e., CFI-rare and CFI-non-rare variants));
| Milestone | GT005 Low Dose [2E10 vg] | GT005 High Dose [2E11 vg] | Untreated Control |
|---|---|---|---|
| Started | 52 | 9 | 37 |
| Randomized part 1 | 10 | 9 | 14 |
| Randomized part 2 | 42 | 0 | 23 |
| Randomized and treated part 1 | 9 | 9 | 0 |
| Randomized and treated part 2 | 18 | 0 | 0 |
| Completed | 6 | 8 | 7 |
| Not completed | 46 | 1 | 30 |
| Withdrew: Death | 3 | 0 | 2 |
| Withdrew: Study terminated by sponsor | 16 | 1 | 25 |
| Withdrew: Withdrawal by subject | 4 | 0 | 3 |
| Withdrew: Sponsor instructions | 23 | 0 | 0 |
The change from baseline to Week 48 in GA area as measured by fundus autofluorescence (FAF)
| mm^2 | GT005 Low Dose [2E10 vg] | GT005 High Dose [2E11 vg] | Untreated Control |
|---|---|---|---|
| Part 1 Week 12 (n=9,8,12) | 0.773 ± 0.2151 | 0.764 ± 0.2159 | 0.482 ± 0.1848 |
| Part 1 Week 24 (n=9,7,9) | 1.338 ± 0.2763 | 1.519 ± 0.2845 | 0.680 ± 0.2500 |
| Part 1 Week 36 (n=6,7,10) | 1.800 ± 0.3740 | 2.044 ± 0.3669 | 1.132 ± 0.3229 |
| Part 1 Week 48 (n=5,8,10) | 2.120 ± 0.3726 | 2.378 ± 0.3414 | 1.144 ± 0.3040 |
The change from baseline to Week 48 in GA area as measured by fundus autofluorescence (FAF)
| mm2 | GT005 Low Dose [2E10 vg] | GT005 High Dose [2E11 vg] | Untreated Control |
|---|---|---|---|
| Part 1 Week 72 (n=5,7,9) | 3.643 ± 0.9725 | 3.149 ± 0.9150 | 1.875 ± 0.8273 |
| Part 1 Week 96 (n=6,8,7) | 4.837 ± 1.0712 | 4.074 ± 1.0305 | 2.796 ± 0.9240 |
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs.
| Participants | GT005 Low Dose [2E10 vg] | GT005 High Dose [2E11 vg] | Untreated Control |
|---|---|---|---|
| Subjects with at least one ocular adverse event for the study eye | 18 | 9 | 2 |
| Subjects with at least one ocular adverse event for the fellow eye | 6 | 3 | 5 |
| Subjects with at least one non-ocular adverse event | 13 | 8 | 14 |
| Subjects with at least one ocular adverse event related to study treatment for the study eye | 3 | 4 | 0 |
| Subjects with at least one non-ocular adverse event related to study treatment | 0 | 0 | 0 |
| Subjects with at least one ocular adverse event related to surgical procedure for the study eye | 12 | 7 | 0 |
| Subjects with at least one non-ocular adverse event related to surgical procedure | 0 | 0 | 0 |
| Subjects with at least one ocular adverse event related to study procedure for the study eye | 1 | 1 | 0 |
| Subjects with at least one non-ocular adverse event related to study procedure | 1 | 0 | 0 |
| Subjects with at least one ocular adverse event leading to study discontinuation for the study eye | 0 | 0 | 0 |
| Subjects with at least one non-ocular adverse event leading to study discontinuation | 3 | 0 | 2 |
| Subjects with at least one ocular adverse event of special interest for the study eye | 4 | 7 | 0 |
| Subjects with at least one ocular adverse event of special interest for the fellow eye | 0 | 0 | 1 |
| Subjects with at least one ocular serious adverse event (SAE) for the study eye | 1 | 0 | 0 |
| Subjects with at least one ocular serious adverse event for the fellow eye | 0 | 0 | 0 |
| Subjects with at least one non-ocular serious adverse event | 5 | 2 | 4 |
| Subjects with at least one ocular serious adverse event related to study treatment for the study eye | 0 | 0 | 0 |
| Subjects with at least one non-ocular serious adverse event related to study treatment | 0 | 0 | 0 |
| Subjects with at least 1 ocular SAE related to surgical procedure - study eye | 0 | 0 | 0 |
| Subjects with at least one non-ocular serious adverse event related to surgical procedure | 0 | 0 | 0 |
| Subjects with at least one ocular serious adverse event related to study procedure for the study eye | 0 | 0 | 0 |
| Subjects with at least one non-ocular serious adverse event related to study procedure | 0 | 0 | 0 |
| Subjects with at least 1 ocular SAE event leading to study discontinuation- study eye | 0 | 0 | 0 |
| Subjects with at least one non-ocular serious adverse event leading to study discontinuation | 3 | 0 | 2 |
| Deaths | 3 | 0 | 2 |
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs. System organ classes are sorted alphabetically, and preferred terms are sorted by decreasing overall frequency within system organ class.
| Participants | GT005 Low Dose [2E10 vg] | GT005 High Dose [2E11 vg] | Untreated Control |
|---|---|---|---|
| Subjects with at least one event | 18 | 9 | 2 |
| Eye disorders | 15 | 9 | 2 |
| -Retinal pigmentation | 3 | 6 | 0 |
| -Conjunctival haemorrhage | 6 | 1 | 0 |
| -Cataract | 3 | 2 | 1 |
| -Cataract nuclear | 2 | 1 | 0 |
| -Eye pain | 1 | 2 | 0 |
| -Retinal haemorrhage | 2 | 1 | 0 |
| -Anterior chamber cell | 1 | 1 | 0 |
| -Blepharitis | 2 | 0 | 0 |
| -Conjunctivitis allergic | 1 | 1 | 0 |
| -Anterior chamber flare | 0 | 1 | 0 |
| -Choroidal detachment | 0 | 1 | 0 |
| -Conjunctival hyperaemia | 1 | 0 | 0 |
| -Dry eye | 1 | 0 | 0 |
| -Eye pruritus | 0 | 0 | 1 |
| -Hypotony maculopathy | 0 | 1 | 0 |
| -Iridocyclitis | 0 | 1 | 0 |
| -Iritis | 1 | 0 | 0 |
| -Keratitis | 1 | 0 | 0 |
| -Lacrimation increased | 0 | 1 | 0 |
| -Macular hole | 1 | 0 | 0 |
| -Meibomian gland dysfunction | 1 | 0 | 0 |
| -Metamorphopsia | 1 | 0 | 0 |
| -Ocular hypertension | 1 | 0 | 0 |
| -Open angle glaucoma | 0 | 1 | 0 |
| -Photophobia | 0 | 1 | 0 |
| -Photopsia | 1 | 0 | 0 |
| -Posterior capsule opacification | 0 | 0 | 1 |
| -Punctate keratitis | 1 | 0 | 0 |
| -Retinal depigmentation | 1 | 0 | 0 |
| -Visual acuity reduced | 1 | 0 | 0 |
| -Visual impairment | 1 | 0 | 0 |
| -Visual snow syndrome | 1 | 0 | 0 |
| -Vitreous floaters | 1 | 0 | 0 |
| -Vitreous haemorrhage | 1 | 0 | 0 |
| Injury, poisoning and procedural complications | 4 | 1 | 0 |
| -Post procedural discomfort | 2 | 0 | 0 |
| -Procedural pain | 1 | 1 | 0 |
| -Suture related complication | 1 | 1 | 0 |
| Investigations | 4 | 3 | 0 |
| -Intraocular pressure increased | 4 | 3 | 0 |
| Skin and subcutaneous tissue disorders | 1 | 0 | 0 |
| -Telangiectasia | 1 | 0 | 0 |
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs.
| Participants | GT005 Low Dose [2E10 vg] | GT005 High Dose [2E11 vg] | Untreated Control |
|---|---|---|---|
| Non-ocular Adverse Events - Summary - Parts 1 and 2 Combined | 13 | 8 | 14 |
Change in GA morphology on multimodal imaging through Week 96. FAF images at Week 5 were introduced via a protocol amendment after most participants had already completed Week 5; therefore, only a minimal number of patients had FAF images taken at Week 5 for Part 1.
| Participants | GT005 Low Dose [2E10 vg] | GT005 High Dose [2E11 vg] | Untreated Control |
|---|---|---|---|
| Part 1 Week 5 (n= 0,2,0) | — | 2 | — |
| Part 1 Week 12 (n=9,8,12) | 8 | 8 | 11 |
| Part 1 Week 24 (n=9,7,10) | 8 | 7 | 10 |
| Part 1 Week 36 (n=6,7,10) | 5 | 7 | 10 |
| Part 1 Week 48 (n=5,8,10) | 5 | 8 | 10 |
| Part 1 Week 72 (n=5,8,9) | 5 | 8 | 9 |
| Part 1 Week 96 (n=6,8,7) | 6 | 8 | 7 |
Change in GA morphology on multimodal imaging through Week 48. For the untreated control group, there were no protocol-specified visits for Weeks 5 and 8. The untreated control participants were immediately discontinued from the study when the study was early terminated; therefore Week 36 and 48 data in part 2 were not applicable for these the untreated control group.
| Participants | GT005 Low Dose [2E10 vg] | GT005 High Dose [2E11 vg] | Untreated Control |
|---|---|---|---|
| Part 2 Week 5 (n= 16,0, 0) | 16 | — | — |
| Part 2 Week 12 (n=17,0,20) | 17 | — | 20 |
| Part 2 Week 24 (n=17,0,11) | 16 | — | 11 |
| Part 2 Week 36 (n=14,0,0) | 13 | — | — |
| Part 2 Week 48 (n=5,0,0) | 5 | — | — |
BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. Min and max possible scores are 0-100 respectively. A higher score represents better visual functioning. For the untreated control group, there were no protocol-specified visits for Weeks 1, 5 and 8.
| Letters read | GT005 Low Dose [2E10 vg] | GT005 High Dose [2E11 vg] | Untreated Control |
|---|---|---|---|
| Part 1 - Week 1 (n=9,9,0) | -4.7 ± 4.04 | -5.2 ± 4.27 | — |
| Part 1 - Week 5 (n=8,9,0) | -1.7 ± 4.08 | -7.6 ± 4.26 | — |
| Part 1 - Week 8 (n=9,9,0) | -1.6 ± 4.03 | -4.5 ± 4.23 | — |
| Part 1 - Week 12 (N=9,9,12) | -2.3 ± 4.03 | -7.5 ± 4.18 | -1.2 ± 3.81 |
| Part 1 - Week 24 (n=9,9,10) | -5.6 ± 4.03 | -12.0 ± 4.18 | -0.4 ± 3.87 |
| Part 1 - Week 36 (n=8,8,10) | -10.0 ± 4.10 | -12.9 ± 4.28 | -1.0 ± 3.89 |
| Part 1 - Week 48 (n=5,8,10) | -8.6 ± 4.52 | -13.3 ± 4.32 | -5.7 ± 3.91 |
| Part 1 - Week 72 (n=5,8,10) | -6.3 ± 4.56 | -9.6 ± 4.34 | -8.9 ± 3.94 |
| Part 1 - Week 96 (n=6,8,7) | -6.5 ± 4.50 | -11.0 ± 4.33 | -7.9 ± 4.30 |
LLD was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. The test was to be performed after BCVA testing, prior to pupil dilation, and distance refraction was to be carried out before Low Luminance Visual Acuity (LLVA) was measured. LLVA was to be measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. The LLD was calculated as the difference between BCVA and LLVA. Initially, letters were to be read at a distance of 4 metres from the chart. If \<20 letters were read at 4 metres, testing at 1 metre should have been performed. LLD was to be reported as number of letters read correctly by the subject. Min and max possible scores are 0-100 respectively. A higher score represents better visual functioning.
| Letters read | GT005 Low Dose [2E10 vg] | GT005 High Dose [2E11 vg] | Untreated Control |
|---|---|---|---|
| Part 1 - Week 12 (N=9,9,12) | 2.0 ± 9.06 | 2.4 ± 22.49 | -2.0 ± 7.21 |
| Part 1 - Week 24 (n=9,9,10) | 2.1 ± 8.40 | 2.9 ± 24.81 | -2.9 ± 7.68 |
| Part 1 - Week 36 (n=8,8,10) | 2.3 ± 15.65 | -7.5 ± 19.41 | -4.0 ± 12.51 |
| Part 1 - Week 48 (n=5,8,10) | 3.0 ± 6.96 | 1.8 ± 26.25 | -6.2 ± 19.99 |
| Part 1 - Week 72 (n=5,8,10) | 4.4 ± 7.57 | 3.1 ± 32.24 | -6.6 ± 21.15 |
| Part 1 - Week 96 (n=6,8,6) | 5.2 ± 8.47 | 1.5 ± 29.17 | -10.5 ± 27.41 |
LLD was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. The test was to be performed after BCVA testing, prior to pupil dilation, and distance refraction was to be carried out before Low Luminance Visual Acuity (LLVA) was measured. LLVA was to be measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. The LLD was calculated as the difference between BCVA and LLVA. Initially, letters were to be read at a distance of 4 metres from the chart. If \<20 letters were read at 4 metres, testing at 1 metre should have been performed. LLD was to be reported as number of letters read correctly by the subject. Min and max possible scores are 0-100 respectively. A higher score represents better visual functioning.
| Letters read | GT005 Low Dose [2E10 vg] | GT005 High Dose [2E11 vg] | Untreated Control |
|---|---|---|---|
| Part 2 - Week 12 (N=18,0,20) | 0.7 ± 10.83 | — | -1.4 ± 11.76 |
| Part 2 - Week 24 (n=17,0,10) | 2.6 ± 9.98 | — | -1.6 ± 20.13 |
| Part 2 - Week 36 (n=14,0,0) | 4.6 ± 11.77 | — | — |
| Part 2 - Week 48 (n=5,0,0) | -2.8 ± 4.32 | — | — |
The maximum reading speed (MRS) represents the highest reading speed an individual can achieve when print size is not a limiting factor. Essentially, it measures how quickly a person can read text when the print is large enough to be easily readable. A higher count represents better visual functioning.
| Words read per minute | GT005 Low Dose [2E10 vg] | GT005 High Dose [2E11 vg] | Untreated Control |
|---|---|---|---|
| Part 1 - Week 24 (n=9,8,9) | 20.384 ± 74.7769 | -36.154 ± 40.3322 | -7.837 ± 21.8918 |
| Part 1 - Week 36 (n=7,7,8) | -15.048 ± 33.0479 | -34.653 ± 27.2693 | -15.245 ± 22.0983 |
| Part 1 - Week 48 (n=4,7,9) | 10.397 ± 11.8698 | -36.285 ± 40.0938 | -6.837 ± 31.6162 |
| Part 1 - Week 72 (n=5,7,9) | -20.796 ± 42.2571 | -44.913 ± 46.7594 | -15.429 ± 30.1012 |
| Part 1 - Week 96 (n=6,5,5) | 10.802 ± 32.1161 | -32.266 ± 36.9172 | -21.602 ± 26.0643 |
A higher count represents better visual functioning. The untreated control participants were immediately discontinued from the study when the study was early terminated; therefore Week 36 and 48 data in part 2 were not applicable for these the untreated control group.
| Words read per minute | GT005 Low Dose [2E10 vg] | GT005 High Dose [2E11 vg] | Untreated Control |
|---|---|---|---|
| Part 2 - Week 24 (n=16,0,10) | 15.581 ± 78.2848 | — | -30.707 ± 27.3225 |
| Part 2 - Week 36 (n=14,0,0) | 9.812 ± 94.4255 | — | — |
| Part 2 - Week 48 (n=5,0,0) | -28.111 ± 38.6209 | — | — |
The FRI index is a patient-reported outcome measure developed specifically for use in GA patients. The FRI index evaluates the level of independence subjects have in performing everyday activities that require reading, such as writing a cheque or reading a prescription. Scores derived from the index range from 1 (unable to do) to 4 (total independence). A higher score represents better visual functioning.
| Scores on a scale | GT005 Low Dose [2E10 vg] | GT005 High Dose [2E11 vg] | Untreated Control |
|---|---|---|---|
| Part 1 - Week 24 (n=9,8,10) | 0.7 ± 3.57 | -1.3 ± 2.55 | -0.3 ± 4.06 |
| Part 1 - Week 36 (n=8,5,10) | -1.0 ± 4.24 | 2.6 ± 4.10 | -0.6 ± 4.72 |
| Part 1 - Week 48 (n=6,7,10) | 0.5 ± 2.43 | -0.1 ± 7.69 | -3.4 ± 4.38 |
| Part 1 - Week 72 (n=5,7,10) | -3.8 ± 4.60 | 0.4 ± 3.41 | -1.3 ± 4.35 |
| Part 1 - Week 96 (n=6,6,7) | -2.7 ± 5.79 | -2.0 ± 3.29 | -0.7 ± 5.53 |
The FRI index is a patient-reported outcome measure developed specifically for use in GA patients. The FRI index evaluates the level of independence subjects have in performing everyday activities that require reading, such as writing a cheque or reading a prescription. Scores derived from the index range from 1 (unable to do) to 4 (total independence). A higher score represents better visual functioning. The untreated control participants were immediately discontinued from the study when the study was early terminated; therefore Week 36 and 48 data in part 2 were not applicable for these the untreated control group.
| Scores on a scale | GT005 Low Dose [2E10 vg] | GT005 High Dose [2E11 vg] | Untreated Control |
|---|---|---|---|
| Part 2 - Week 24 (n=17,0,9) | -0.4 ± 2.83 | — | 0.4 ± 6.86 |
| Part 2 - Week 36 (n=14,0,0) | -1.7 ± 3.83 | — | — |
| Part 2 - Week 48 (n=5,0,0) | 0.4 ± 5.13 | — | — |
The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains. The NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales.
| Scores on a Scale | GT005 Low Dose [2E10 vg] | GT005 High Dose [2E11 vg] | Untreated Control |
|---|---|---|---|
| Part 1 - Week 24 (n=9,9,10) | -2.312 ± 5.7079 | -3.755 ± 7.4470 | -7.304 ± 12.5136 |
| Part 1 - Week 36 (n=8,6,10) | -4.400 ± 11.1307 | 1.960 ± 9.0113 | -4.706 ± 11.8617 |
| Part 1 - Week 48 (n=6,8,10) | -6.439 ± 24.2128 | -6.810 ± 11.5980 | -4.091 ± 15.3598 |
| Part 1 - Week 72 (n=5,8,10) | -8.698 ± 22.1289 | -3.332 ± 8.1470 | -3.826 ± 11.0029 |
| Part 1 - Week 96 (n=6,7,7) | -10.352 ± 23.9470 | 0.171 ± 11.3543 | -10.700 ± 11.6900 |
The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains. The NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better visual functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A composite score is derived based on the average of the 11 subscales. The untreated control participants were immediately discontinued from the study when the study was early terminated; therefore Week 36 and 48 data in part 2 were not applicable for these the untreated control group.
| Scores on a Scale | GT005 Low Dose [2E10 vg] | GT005 High Dose [2E11 vg] | Untreated Control |
|---|---|---|---|
| Part 2 - Week 24 (n=17,0,8) | -4.034 ± 6.8881 | — | -3.070 ± 7.4251 |
| Part 2 - Week 36 (n=14,0,0) | -2.733 ± 7.9219 | — | — |
| Part 2 - Week 48 (n=5,0,0) | -0.530 ± 6.9722 | — | — |
Collected over Adverse events are reported from randomization up to end of study, for a maximum timeframe of approximately 96 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GT005 Low Dose [2E10 vg] | 3/52 (5.8%) | 5/52 (9.6%) | 19/52 (36.5%) |
| GT005 High Dose [2E11 vg] | 0/9 (0%) | 2/9 (22.2%) | 9/9 (100%) |
| Untreated Control | 2/37 (5.4%) | 4/37 (10.8%) | 16/37 (43.2%) |
| Overall | 5/98 (5.1%) | 11/98 (11.2%) | 44/98 (44.9%) |
| Event | GT005 Low Dose [2E10 vg] | GT005 High Dose [2E11 vg] | Untreated Control | Overall |
|---|---|---|---|---|
| GastroenteritisInfections and infestations | 0/52 | 1/9 | 0/37 | 1/98 |
| Amyotrophic lateral sclerosisNervous system disorders | 0/52 | 1/9 | 0/37 | 1/98 |
| Staphylococcal infectionInfections and infestations | 0/52 | 0/9 | 1/37 | 1/98 |
| Urinary tract infectionInfections and infestations | 0/52 | 0/9 | 1/37 | 1/98 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/52 | 0/9 | 1/37 | 1/98 |
| Cerebrovascular accidentNervous system disorders | 0/52 | 0/9 | 1/37 | 1/98 |
| EncephalopathyNervous system disorders | 0/52 | 0/9 | 1/37 | 1/98 |
| SciaticaNervous system disorders | 0/52 | 0/9 | 1/37 | 1/98 |
| SeizureNervous system disorders | 0/52 | 0/9 | 1/37 | 1/98 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/52 | 0/9 | 1/37 | 1/98 |
| Event | GT005 Low Dose [2E10 vg] | GT005 High Dose [2E11 vg] | Untreated Control | Overall |
|---|---|---|---|---|
| Retinal pigmentation - Study eyeEye disorders | 3/52 | 6/9 | 0/37 | 9/98 |
| Intraocular pressure increased - Study eyeInvestigations | 4/52 | 3/9 | 0/37 | 7/98 |
| Cataract - Study eyeEye disorders | 3/52 | 2/9 | 1/37 | 6/98 |
| Eye pain - Study eyeEye disorders | 1/52 | 2/9 | 0/37 | 3/98 |
| COVID-19Infections and infestations | 3/52 | 2/9 | 1/37 | 6/98 |
| Conjunctival haemorrhage - Study eyeEye disorders | 6/52 | 1/9 | 0/37 | 7/98 |
| AnaemiaBlood and lymphatic system disorders | 0/52 | 1/9 | 1/37 | 2/98 |
| Anterior chamber cell - Study eyeEye disorders | 1/52 | 1/9 | 0/37 | 2/98 |
| Anterior chamber flare - Study eyeEye disorders | 0/52 | 1/9 | 0/37 | 1/98 |
| Cataract - Fellow eyeEye disorders | 0/52 | 1/9 | 2/37 | 3/98 |
Full Analysis Set (FAS) as described in the study protocol, which included all participants who were randomized to GT005 or untreated control. Because genotype may influence disease progression, these parts were considered in the analysis of the efficacy endpoints only, but not safety and not demographics, per the SAP and protocol.
| Age, Continuous(years) | GT005 Low Dose [2E10 vg] | GT005 High Dose [2E11 vg] | Untreated Control | Total |
|---|---|---|---|---|
| Mean | 76.8 ± 7.33 | 72.7 ± 8.96 | 75.2 ± 7.07 | 75.8 ± 7.41 |
| Sex: Female, Male(Participants) | GT005 Low Dose [2E10 vg] | GT005 High Dose [2E11 vg] | Untreated Control | Total |
|---|---|---|---|---|
| Female | 34 | 5 | 18 | 57 |
| Male | 18 | 4 | 19 | 41 |
| Race (NIH/OMB)(Participants) | GT005 Low Dose [2E10 vg] | GT005 High Dose [2E11 vg] | Untreated Control | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 51 | 7 | 35 | 93 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 2 | 4 |
Documents are hosted by the registry — open the source record to download them.
This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gyroscope Therapeutics Limited